Nurix Therapeutics (NRIX) Jefferies Global Healthcare Conference 2026 summary

Key program updates

• Upcoming EHA conference will feature new data on the BTK degrader bexobrutideg in CLL, including results from treatment-naive and BTK/BCL2 inhibitor-naive patients.

• Phase I-B/II combination trial of bexobrutideg with venetoclax and anti-CD20 antibodies is set to start mid-year, aiming for fixed-duration therapy.

• Phase III monotherapy trial in second-line CLL (post-BTK inhibitor progression) will also begin mid-year, enrolling about 600 patients across 20+ countries.

• Pivotal phase II trial in later-line CLL is ongoing, with response rates of 70–80% in heavily pretreated patients and 85%+ in earlier lines.

• NHL expansion is underway, with dramatic responses and 85% response rates in various subtypes; further data expected at ASH.

Differentiation and clinical rationale

• Bexobrutideg shows high selectivity, potency, and a favorable safety profile, including low infection and bleeding risk, and no liver enzyme elevation.

• Degrader mechanism enables catalytic protein removal, potentially offering superior efficacy and safety over inhibitors.

• Clinical rationale supports using the most effective therapy first to maximize patient outcomes; degraders may become frontline agents.

• Degraders can overcome resistance mutations seen with BTK inhibitors, with rare exceptions that are clinically manageable.

• Combination strategies, especially with venetoclax, are expected to address broader mutation profiles.

Corporate strategy and partnerships

• Partnership is favored for frontline and combination trials due to cost and complexity, with existing collaborations with Sanofi, Gilead, and Pfizer.

• Bex-deg is positioned as a foundational therapy across CLL, NHL, and autoimmune indications, with a strategy for multi-indication global partnerships.

• Well-capitalized to fund ongoing and planned trials, including phase III in CLL and initiation of I&I programs.